Search En/Fr

Media Change Category

Spread the Nanonews

Founded in 2003, Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology: NanoXray, enhances radiotherapy energy with a view to provide a new and more efficient way to treat cancer patients.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck cancers, prostate cancer, rectal cancer and liver cancers (HCC and liver metastases).

In parallel, Nanobiotix has launched a preclinical program in immuno-oncology.

Cancer is a major cause of mortality in the world, and its incidence has been steadily increasing since 1980. According to the World Health Organization (WHO), there will be 15 million new cases of cancer worldwide in 2020. More than 90% of cancer-related deaths occur by the spread of malignant cells to vital organs, a process called metastasis.